Clearside Biomedical

Inactive

CLSD (NasdaqGM)

Clearside Biomedical, Inc. is a biopharmaceutical company focused on delivering therapies to the back of the eye via the suprachoroidal space. Its approved product XIPERE is a triamcinolone acetonide injectable suspension for macular edema from uveitis. It is developing CLS-AX, an axitinib injectable suspension for suprachoroidal delivery for wet AMD, and has multiple collaborations. Incorporated in 2011, HQ in Alpharetta, GA. On Nov 23, 2025, it filed for Chapter 11 bankruptcy.